RxDoctor Payments DataLook up a doctor →

Patricia Damron-Robinson, NP

Adult Health · Merrillville, INNPI 1831343870

Payments from drug & device makers

$19,897in general payments, 2019–2025

Across 549 payments — averaging $36.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • Incyte Corporation$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$926
  • plus $8K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$4,133
AstraZeneca(2 entities)59$2,385
Johnson & Johnson(2 entities)39$1,527
Incyte Corporation36$1,364
E.r. Squibb & Sons, L.L.C.27$1,203
Pfizer18$926
Genentech USA, Inc.26$696
Amgen24$594
Seagen Inc.12$573
Daiichi Sankyo Inc.13$474
Bristol Myers Squibb20$471
Intrinsiq Specialty Solutions, Inc.4$382
Astellas Pharma US Inc17$373
Jazz Pharmaceuticals Inc.10$350
Takeda Pharmaceuticals U.S.A., Inc.12$338
Merck15$296
Regeneron Healthcare Solutions, Inc.11$289
AbbVie13$239
Gilead(2 entities)8$235
Mirati Therapeutics, Inc.7$231
Pharmacyclics LLC, An Abbvie Company6$204
Exelixis Inc.5$163
Sanofi8$161
GSK9$155
Beone Medicines USA, Inc.1$149
Ipsen Biopharmaceuticals, Inc6$147
Sobi, Inc7$131
Celltrion USA Inc.2$130
EMD Serono, Inc.3$115
ASD Specialty Healthcare, LLC1$95
Pharmacosmos Therapeutics Inc.3$83
Array Biopharma Inc4$82
Eisai Inc.4$77
Stemline Therapeutics Inc.3$76
Lilly USA, LLC3$73
Puma Biotechnology, Inc.4$70
Coherus Oncology, Inc.3$68
Pharmaessentia USA Corporation2$54
Sumitomo Pharma America, Inc.2$53
Clovis Oncology, Inc.3$52
Myovant Sciences Inc.2$51
Global Blood Therapeutics, Inc.2$44
Azurity Pharmaceuticals, Inc.2$43
Rigel Pharmaceuticals, Inc.2$42
Octapharma USA, Inc.2$42
Bayer2$40
Amneal Pharmaceuticals LLC2$40
Deciphera Pharmaceuticals Inc.2$38
Syndax Pharmaceuticals, Inc.1$31
Morphosys, US Inc.2$30
Taiho Oncology, Inc.2$29
Agios Pharmaceuticals, Inc.1$29
Medtronic1$27
Fennec Pharmaceuticals, Inc.1$26
EUSA Pharma (US) LLC1$25
Blueprint Medicines Corporation1$23
Curium US LLC1$21
Mayne Pharma Commercial LLC1$21
Boehringer Ingelheim1$19
Beigene USA, Inc.1$17

How this compares

$19,897 in reported general payments places this provider in the 95th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana →

Medicare billing

Part B allowed, 2024
$160,065
Medicare patients
132
Services billed
5,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adult health in Merrillville

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →